There are two noteworthy updates from a notice issued late this week on what the FDA says could cause serious illness or ...
On December 27, 2024, the US Food and Drug Administration (FDA) published its final rule to update the definition for “healthy” claims on food ...
In the face of tough competition from Apellis and a recent setback with prescribers, Astellas’ geographic atrophy (GA) med ...
The U.S. Food and Drug Administration (FDA) has given its second most serious risk level, Class II, to a product from D.
GOMEKLI is the first and only medicine approved for both adults and children with NF1-PN –– Approval based on positive data ...
On January 16, 2025, the U.S. Food and Drug Administration (FDA) announced a significant regulatory change by revoking the authorization for use ...
A pecan nut product that was recalled due to undeclared walnuts has been given a Class II classification by the food agency.
PharmaTher expects to submit the MINOR AMENDMENT to the CRL by end-February 2025 and expects a new approval date for a Q2-2025 FDA approval of ketamineTORONTO, Feb. 12, 2025 (GLOBE NEWSWIRE) -- ...
Changes to the FDA labeling guidance in support of FALCPA include alterations to the definitions of “major” food allergens ...
The Food and Drug Administration has classified a recall of 60 different doughnut products to its second-highest level, the agency announced earlier this week in an update to its website.
Dr. Gabriel A. Brooks discusses the recent FDA product labeling update for Xeloda and 5-FU which aims to highlight risks associated with DPD deficiency.
The FDA has updated the product labeling for Xeloda and 5-FU to highlight the risks associated with dihydropyrimidine ...